Cancer Prevention Pharmaceuticals (Cancer Prevention Pharmaceuticals) Net Margin % : -320.13% (As of Mar. 2016)

View and export this data going back to 2016. Start your Free Trial

What is Cancer Prevention Pharmaceuticals Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Cancer Prevention Pharmaceuticals's Net Income for the three months ended in Mar. 2016 was $-3.32 Mil. Cancer Prevention Pharmaceuticals's Revenue for the three months ended in Mar. 2016 was $1.04 Mil. Therefore, Cancer Prevention Pharmaceuticals's net margin for the quarter that ended in Mar. 2016 was -320.13%.

The historical rank and industry rank for Cancer Prevention Pharmaceuticals's Net Margin % or its related term are showing as below:

CPP's Net Margin % is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 3.25
* Ranked among companies with meaningful Net Margin % only.

Cancer Prevention Pharmaceuticals Net Margin % Historical Data

The historical data trend for Cancer Prevention Pharmaceuticals's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cancer Prevention Pharmaceuticals Net Margin % Chart

Cancer Prevention Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Net Margin %

-2,915.84

-1,237.53

-152.92

Cancer Prevention Pharmaceuticals Quarterly Data
	Dec13	Dec14	Mar15	Sep15	Dec15	Mar16
Net Margin %	Get a 7-Day Free Trial			-1,328.10	-1,660.33	-	-1,980.17	-320.13

Competitive Comparison of Cancer Prevention Pharmaceuticals's Net Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Cancer Prevention Pharmaceuticals's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cancer Prevention Pharmaceuticals's Net Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cancer Prevention Pharmaceuticals's Net Margin % distribution charts can be found below:

* The bar in red indicates where Cancer Prevention Pharmaceuticals's Net Margin % falls into.

Cancer Prevention Pharmaceuticals Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Cancer Prevention Pharmaceuticals's Net Margin for the fiscal year that ended in Dec. 2015 is calculated as

Net Margin	=	Net Income (A: Dec. 2015 )	/	Revenue (A: Dec. 2015 )
	=	-5.681	/	3.715
	=	-152.92 %

Cancer Prevention Pharmaceuticals's Net Margin for the quarter that ended in Mar. 2016 is calculated as

Net Margin	=	Net Income (Q: Mar. 2016 )	/	Revenue (Q: Mar. 2016 )
	=	-3.323	/	1.038
	=	-320.13 %

Cancer Prevention Pharmaceuticals (AMEX:CPP) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Cancer Prevention Pharmaceuticals Net Margin % Related Terms

Thank you for viewing the detailed overview of Cancer Prevention Pharmaceuticals's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Cancer Prevention Pharmaceuticals (Cancer Prevention Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cancer Prevention Pharmaceuticals Inc (AMEX:CPP) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.canprevent.com

Cancer Prevention Pharmaceuticals Inc is a pharmaceutical company. It was originally incorporated under the laws of the state of Arizona on June 9, 2008, as Cancer Prevention Pharmaceuticals, LLC and on December 22, 2009, Cancer Prevention Pharmaceuticals, Inc. was incorporated in the state of Delaware. The Company currently operates mainly in the development and commercialization of compound CPP-1X, otherwise known as DFMO or eflornithine. It is involved in familial adenomatous polyposis, neuroblastoma and the prevention of recurrence in colon cancer survivors. However, CPP also has therapeutic prevention approaches for prostate cancer, breast cancer, and skin cancers which will be developed together with the National Cancer Institute (as resources become available in the future) and multiple academic partners. Its competitors are Marina Biotech, Inc., SLA Pharma AG, StemSynergy Therapeutics, Inc. and Thetis Pharmaceuticals LLC. The Company holds license to approximately six issued patents in the United States. The Company's activities are subject to risks and uncertainties including failure to obtain required regulatory approvals to market the products, once developed, in the USA or foreign markets.